Esker Secures US Patent for Machine Learning Document Data Extraction

Date:

Esker, a leading provider of AI-driven process automation solutions, has announced the issuance of a US patent for its machine learning technology. The AI-powered solutions, spanning both the source-to-pay (S2P) and order-to-cash (O2C) cycles, are designed to reduce repetitive and low-value tasks, enabling businesses to cut costs and improve efficiency. Specifically, the newly patented AI technology focuses on automating the extraction of accurate data from incoming documents, freeing companies from the time-consuming and expensive manual entry of information for invoices, orders, and other documents. Using both traditional and machine learning algorithms, the technology identifies data fields, makes routing decisions, and suggests next actions, with the goal of reducing touches during processing as much as possible. The combination of human and artificial intelligence allows Esker’s technology to increase the accuracy over time by learning from user corrections.

See also  Broadridge Secures Patent for Machine Learning Technology Focused on Securities-Based Lending

Frequently Asked Questions (FAQs) Related to the Above News

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.